港股異動丨敏華控股漲近5% 大行紛紛唱多
格隆匯11月27日丨敏華控股(1999.HK)漲近5%,報5.84港元,總市值222.7億港元。

匯豐環球研究最近發表報告指,敏華致力在中國推出受年輕消費者歡迎的新梳化產品,使內地市場的線上及線下銷售均有快速增長。集團上半年在中國的銷售按年上升11.8%,而總收入中有52%來自該市場。該行預期,集團今財年中國市場的銷售收入將按年增長16%至64億元。匯豐上調對敏華控股目標價,由5港元升至6.47港元,評級維持“買入”。
中金公司亦發佈報告,認為在公司內銷收入佔比提升、外銷業務風險釋放驅動下,公司估值中樞有望持續提升,上調其目標價17.6%至6.00港元,維持“跑贏行業”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.